News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention and treatment of viral infections like HIV and COVID-19. The conference ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound. A virologist ...

THURSDAY, March 20, 2025 (HealthDay News) -- For household contacts of individuals with COVID-19, taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well ...

based on data from a phase 3 trial presented at the 2025 Conference on Retroviruses and Opportunistic Infections. Ensitrelvir, an oral SARS-CoV-2 3CL protease inhibitor, is approved in Japan for ...

Well! We’ve come a long way since CROI 2020 — for many of us, the first all-virtual conference, organized a just days following the first reports of what would become the COVID-19 pandemic.

Data derived from Tewari S, et al. Abstract 1014. Presented at: Conference on Retroviruses and Opportunistic Infections; March 9-12, 2025; San Francisco. “This cannot only put their own health ...